logo
  

FDA Seeks Public Comments For Marketing Philip Morris' IQOS 3 As MRTP - Quick Facts

Philip Morris International (PM) announced Friday that the U.S. Food and Drug Administration (FDA) has opened a public comment period on application seeking authorization to market its IQOS 3 electrically heated tobacco system as a Modified Risk Tobacco Product (MRTP).

The application requests the same reduced exposure modification orders granted on July 7, 2020, for the IQOS 2.4 system—the first, and only, electronic nicotine product to be granted marketing orders through the FDA's MRTP process.

To authorize MRTP consumer communications, the FDA's Center for Tobacco Products is required by law to conclude that a product is appropriate to promote the public health.

The IQOS 3 device contains a number of technological advancements, compared to the IQOS 2.4 device, including longer battery life and quicker recharge between uses.

It was authorized for sale in the U.S. via the FDA's pre-market review process on December 7, 2020, having met the standard that permitting its sale is appropriate to protect public health.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
Follow RTT